医学
肝细胞癌
超声造影
危险系数
超声波
放射科
内科学
置信区间
比例危险模型
总体生存率
胃肠病学
作者
Shouxin Zhang,Qingyue Wei,Yini Huang,Yao Zhao,Cuiju Yan,Xuebin Zou,Jing Han,Qing Li,Rushuang Mao,Ying Liao,Lan Cao,Min Lin,Xiaoshuang Zhou,Xiaofeng Tang,Yixin Hu,Lingling Li,Yuanyuan Wang,Jinhua Yu,Jianhua Zhou
标识
DOI:10.3389/fonc.2022.878061
摘要
Microvascular invasion (MVI) is a well-known risk factor for poor prognosis in hepatocellular carcinoma (HCC). This study aimed to develop a deep convolutional neural network (DCNN) model based on contrast-enhanced ultrasound (CEUS) to predict MVI, and thus to predict prognosis in patients with HCC.A total of 436 patients with surgically resected HCC who underwent preoperative CEUS were retrospectively enrolled. Patients were divided into training (n = 301), validation (n = 102), and test (n = 33) sets. A clinical model (Clinical model), a CEUS video-based DCNN model (CEUS-DCNN model), and a fusion model based on CEUS video and clinical variables (CECL-DCNN model) were built to predict MVI. Survival analysis was used to evaluate the clinical performance of the predicted MVI.Compared with the Clinical model, the CEUS-DCNN model exhibited similar sensitivity, but higher specificity (71.4% vs. 38.1%, p = 0.03) in the test group. The CECL-DCNN model showed significantly higher specificity (81.0% vs. 38.1%, p = 0.005) and accuracy (78.8% vs. 51.5%, p = 0.009) than the Clinical model, with an AUC of 0.865. The Clinical predicted MVI could not significantly distinguish OS or RFS (both p > 0.05), while the CEUS-DCNN predicted MVI could only predict the earlier recurrence (hazard ratio [HR] with 95% confidence interval [CI 2.92 [1.1-7.75], p = 0.024). However, the CECL-DCNN predicted MVI was a significant prognostic factor for both OS (HR with 95% CI: 6.03 [1.7-21.39], p = 0.009) and RFS (HR with 95% CI: 3.3 [1.23-8.91], p = 0.011) in the test group.The proposed CECL-DCNN model based on preoperative CEUS video can serve as a noninvasive tool to predict MVI status in HCC, thereby predicting poor prognosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI